早期非小细胞肺癌合并间质性肺病立体定向放疗的剂量学结果:ASPIRE-ILD试验二次分析
该二次分析对39例早期肺癌合并间质性肺病患者接受50 Gy/5次隔日SABR的剂量学进行中心审查,评估靶区与危及器官剂量及基线因素与结局的相关性。结果显示局部控制随肿瘤尺寸增大而下降,≥2级不良事件风险随心脏最大剂量、心脏D15cc及肿瘤周围纤维化程度增加而升高;戒烟与特发性肺纤维化诊断与6个月生活质量评分改善相关。
要点
- 肿瘤尺寸增大(iGTV或PTV)与局部控制下降相关(P=.038;P=.033)。
- 心脏最大剂量(P=.020)和心脏D15cc(P=.025)升高与≥2级不良事件风险增加相关。
- 肿瘤周围肺组织纤维化密度升高与≥2级不良事件风险增加相关(P=.006)。
核心结论
- SABR治疗合并间质性肺病的早期肺癌时,心脏剂量与戒烟等若干因素与临床相关结局存在关联。
- SABR照射肺高纤维化区域与更高毒性相关,戒烟可能对治疗后生活质量保护具有重要意义。
研究设计与样本
- ASPIRE-ILD试验的二次剂量学分析,对放疗计划进行中心审查。
- 队列纳入39例接受SABR(50 Gy分5次,隔日照射)的早期肺癌合并间质性肺病患者。
- 采用描述性统计评估靶区与危及器官剂量,并用未校正Cox比例风险回归和逻辑回归分析预测因素,线性回归分析生活质量评分预测因素。
主要发现
- 平均内大体肿瘤体积为12.0±11.2 cc,计划靶区体积为33.9±22.0 cc,平均最大剂量为64.2±6.3 Gy。
- 未校正分析中,局部控制随肿瘤尺寸增大而下降(iGTV P=.038;PTV P=.033)。
- ≥2级不良事件风险随心脏最大剂量(P=.020)、心脏D15cc(P=.025)及肿瘤周围纤维化程度(PTV周围肺组织Hounsfield单位密度,P=.006)升高而增加。
- 总生存较差与ILD亚型、既往或当前ILD治疗、家庭氧疗及较大靶区尺寸相关。
- 戒烟和特发性肺纤维化诊断与6个月时FACT-Lung评分改善相关。
关键数值与推荐
- SABR方案为50 Gy分5次,隔日照射。
- 局部控制下降与iGTV尺寸(P=.038)或PTV尺寸(P=.033)增大相关。
- ≥2级不良事件风险增加与心脏最大剂量(P=.020)、心脏D15cc(P=.025)及PTV周围肺组织Hounsfield单位密度(P=.006)升高相关。
临床怎么用
- 对于合并间质性肺病的早期肺癌患者,SABR计划制定时应关注心脏最大剂量和心脏D15cc,以降低≥2级不良事件风险。
- 肿瘤周围肺组织纤维化密度高的患者接受SABR时毒性风险更高,患者选择和计划设计需予以考虑。
- 戒烟可能有助于保护SABR治疗后的生活质量。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: SABR therapy in the setting of interstitial lung disease (ILD) is associated with higher toxicity risks. This dosimetric analysis of the ASPIRE-ILD trial evaluates doses delivered to targets and organs at risk, and correlations between baseline factors and outcomes, to better inform patient selection and treatment planning. METHODS AND MATERIALS: Radiation plans were centrally reviewed, and descriptive statistics were used to assess doses to targets and organs at risk. Unadjusted Cox proportional hazards and logistic regression were performed to identify predictors of overall survival, local control, and related adverse events. Linear regression was performed to identify significant predictors of the Functional Assessment of Cancer Therapy: Lung. RESULTS: The cohort included 39 patients with early-stage lung cancer and ILD treated with SABR (50 Gy in 5 fractions every other day). The mean internal gross tumor volume and planning target volume (PTV) were 12.0 ± 11.2 cc and 33.9 ± 22.0 cc, respectively. The mean ± SD maximum dose was 64.2 ± 6.3 Gy. On unadjusted analyses, local control decreased with increasing tumor size [measured as either internal gross tumor volume size (P = .038) or PTV size (P = .033)]. The risk of grade ≥2 adverse events increased with higher heart maximum dose (P = .020) and heart D15cc (P = .025), and with increasing fibrosis surrounding the tumor [measured as the Hounsfield unit density of lung immediately surrounding the PTV (P = .006)]. Worse overall survival was associated with ILD subtype, previous or current ILD treatment, home oxygen use, and larger target sizes. Smoking cessation and a diagnosis of idiopathic pulmonary fibrosis were associated with improved Functional Assessment of Cancer Therapy: Lung scores at 6 months. CONCLUSIONS: Several factors were associated with clinically relevant outcomes after SABR in patients with ILD, including radiation dose to the heart and smoking cessation. SABR delivered to highly fibrotic areas of the lung was associated with higher toxicity. Smoking cessation may be important in preserving quality of life after treatment.
引用
- Dang A, Palma DA, Wang E, et al. Dosimetric Outcomes for Stereotactic Radiation Therapy in Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Secondary Analysis of the ASPIRE-ILD Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 41033610. doi:10.1016/j.ijrobp.2025.09.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。